Skip to main content
Top
Published in: Annals of Surgical Oncology 8/2007

01-08-2007 | Breast Oncology

Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988–2003 SEER Data

Authors: Jennifer Gnerlich, MD, Donna B. Jeffe, PhD, Anjali D. Deshpande, PhD, Courtney Beers, BA, Christina Zander, BA, Julie A. Margenthaler, MD

Published in: Annals of Surgical Oncology | Issue 8/2007

Login to get access

Abstract

Background

Primary treatments for stage IV breast cancer are chemotherapy and radiation, with surgery usually reserved for tumor-related complications. We sought to determine whether surgical removal of the primary tumor provides a survival advantage for women with metastatic breast cancer.

Methods

We conducted a retrospective, population-based cohort study by using the 1988–2003 Surveillance, Epidemiology, and End Results (SEER) program data. By use of multivariate Cox regression models, overall survival in women with stage IV disease was compared between women who underwent surgical excision of their breast tumor with women who did not, controlling for potential confounding demographic, tumor- and treatment-related variables, and propensity scores (accounting for variables associated with the likelihood of having surgery).

Results

Of 9734 SEER patients with stage IV breast cancer, 47% underwent breast cancer surgery and 53% did not. Median survival was longer for women who had surgery than for women who did not, both among women who were alive at the end of the study period (36.00 vs. 21.00 months; P < .001) and among women who had died during follow-up (18.00 vs. 7.00 months; P < .001). After controlling for potential confounding variables and propensity scores, patients who underwent surgery were less likely to die during the study period compared with women who did not undergo surgery (adjusted hazard ratio, .63, 95% confidence interval, .60–.66).

Conclusions

Analysis of the 1988–2003 SEER data indicated that extirpation of the primary breast tumor in patients with stage IV disease was associated with a marked reduction in risk of dying after controlling for variables associated with survival.
Literature
1.
go back to reference Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995;13:1453–8PubMed Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995;13:1453–8PubMed
3.
go back to reference Bernard-Marty C, Cardoso F, Piccaart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncology 2004;9:617–32CrossRef Bernard-Marty C, Cardoso F, Piccaart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncology 2004;9:617–32CrossRef
4.
go back to reference Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003;8:241–51PubMedCrossRef Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003;8:241–51PubMedCrossRef
6.
go back to reference Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620–7PubMedCrossRef Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620–7PubMedCrossRef
7.
go back to reference Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776–82PubMedCrossRef Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776–82PubMedCrossRef
8.
go back to reference Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743–9PubMedCrossRef Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743–9PubMedCrossRef
9.
go back to reference Griffiths CT, Fuller AR. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Symposium on Gynecologic Cancer. Surg Clin North Am 1978;58:131–42PubMed Griffiths CT, Fuller AR. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Symposium on Gynecologic Cancer. Surg Clin North Am 1978;58:131–42PubMed
10.
go back to reference Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000;19:42–8PubMedCrossRef Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000;19:42–8PubMedCrossRef
11.
go back to reference Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559–64PubMedCrossRef Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559–64PubMedCrossRef
12.
go back to reference Griffiths CT, Parker LM, Lee S, Finkler NJ. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer 2002;12:323–31PubMedCrossRef Griffiths CT, Parker LM, Lee S, Finkler NJ. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer 2002;12:323–31PubMedCrossRef
13.
go back to reference Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727–33PubMed Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727–33PubMed
14.
go back to reference Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001;345:1655–9PubMedCrossRef Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001;345:1655–9PubMedCrossRef
15.
go back to reference Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000;135:530–4PubMedCrossRef Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000;135:530–4PubMedCrossRef
16.
go back to reference Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233–41PubMedCrossRef Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233–41PubMedCrossRef
17.
go back to reference Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–25PubMedCrossRef Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–25PubMedCrossRef
18.
go back to reference Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004;136:650–9PubMedCrossRef Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004;136:650–9PubMedCrossRef
19.
go back to reference Hallissey MT, Allum WH, Roginski C, Fielding JWL. Palliative surgery for gastric cancer. Cancer 1988;62:440–4PubMedCrossRef Hallissey MT, Allum WH, Roginski C, Fielding JWL. Palliative surgery for gastric cancer. Cancer 1988;62:440–4PubMedCrossRef
21.
go back to reference Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149–56PubMedCrossRef Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149–56PubMedCrossRef
22.
go back to reference Carmichael AR, Anderson EDC, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2002;29:17–9CrossRef Carmichael AR, Anderson EDC, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2002;29:17–9CrossRef
23.
go back to reference Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–91PubMedCrossRef Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–91PubMedCrossRef
24.
go back to reference Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004;6:R372–4PubMedCrossRef Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004;6:R372–4PubMedCrossRef
25.
go back to reference Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001;65:217–24PubMedCrossRef Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001;65:217–24PubMedCrossRef
26.
go back to reference O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315–28PubMedCrossRef O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315–28PubMedCrossRef
27.
go back to reference Danna EA, Sinha P, Gilbert M, et al. Surgical removal of the primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205–11PubMedCrossRef Danna EA, Sinha P, Gilbert M, et al. Surgical removal of the primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205–11PubMedCrossRef
28.
go back to reference Dooley WC. A surgical indication in incurable breast cancer (editorial). Ann of Surg Oncol 2006;13:759–60CrossRef Dooley WC. A surgical indication in incurable breast cancer (editorial). Ann of Surg Oncol 2006;13:759–60CrossRef
29.
go back to reference Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133–46PubMedCrossRef Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133–46PubMedCrossRef
Metadata
Title
Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988–2003 SEER Data
Authors
Jennifer Gnerlich, MD
Donna B. Jeffe, PhD
Anjali D. Deshpande, PhD
Courtney Beers, BA
Christina Zander, BA
Julie A. Margenthaler, MD
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9438-0

Other articles of this Issue 8/2007

Annals of Surgical Oncology 8/2007 Go to the issue